Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on developing therapies for rare diseases with limited or no treatment options, aiming to provide life-changing therapeutics to affected individuals [3]. Upcoming Events - Members of Zevra's executive leadership team will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on August 13, 2025, at 1:00 p.m. ET [1]. - Management will also be available for one-on-one meetings with registered conference attendees [2]. Investor Relations - A live webcast of the fireside chat will be accessible via the "Events & Presentations" section on Zevra's Investor Relations website [2].

Core Insights - Catalyst Pharmaceuticals, Inc. has appointed Dr. Daniel Curran to its Board of Directors, bringing over 25 years of pharmaceutical experience [1][2] - Dr. Curran's expertise includes strategy, business development, and rare disease knowledge, which will support Catalyst's growth strategy [3][4] - The company has a strong foundation in delivering innovative therapies for rare diseases and aims to expand its global presence [7] Company Overview - Catalyst Pharmaceuticals is focused on improving the lives of patients with rare diseases through innovative therapies [7] - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list [7] - Catalyst emphasizes patient care and accessibility, providing comprehensive support services to ensure patients receive necessary treatments [7] Leadership Background - Dr. Curran has held significant roles at Takeda Pharmaceutical Company, including Senior Vice President and Head of the Rare Genetics and Hematology Therapeutic Area Unit [3][4] - He has also served in leadership positions at Millennium Pharmaceuticals and DuPont Merck Pharmaceuticals [4][5] - Dr. Curran holds an M.D. from the University of Pennsylvania, an M.B.A. from The Wharton School, and a B.S. in chemistry from King's College [6]

Core Points - Zevra Therapeutics, Inc. will report its corporate and financial results for Q2 2025 on August 12, 2025, after market close, followed by a conference call at 4:30 p.m. ET [1] - The audio webcast of the conference call will be available on Zevra's Investor Relations website, with a replay accessible for 90 days [2] - Zevra is a commercial-stage company focused on developing therapies for rare diseases, aiming to provide life-changing treatments where options are limited or nonexistent [3] Company Overview - Zevra Therapeutics combines science, data, and patient needs to create transformational therapies for rare diseases [3] - The company employs unique, data-driven strategies for drug development and commercialization to address complex challenges in making new therapies available [3]

Financial Data and Key Metrics Changes - Total net revenues increased by 43.6% year over year to $141,400,000, with significant contributions from all products [5][25]. - Net income before income taxes for Q1 2025 was $71,300,000, a 145% increase year over year compared to $29,100,000 in Q1 2024 [27]. - GAAP net income for Q1 2025 was $56,700,000 or $0.47 per basic share, up 144% from $23,300,000 or $0.20 per basic share in Q1 2024 [27][29]. - Non-GAAP net income for Q1 2025 was $86,600,000 or $0.71 per basic share, compared to $46,800,000 or $0.40 per basic share in Q1 2024 [29]. Business Line Data and Key Metrics Changes - Firdapse generated revenue of $83,700,000, a 25.3% increase year over year, driven by strong adoption among newly diagnosed patients [7][26]. - Agamry's net product revenues totaled $22,000,000, compared to $1,200,000 in Q1 2024, reflecting its first full quarter of sales [9][26]. - Fycompa's net product revenue was $35,600,000, representing a year-over-year growth of 17.1% [11][27]. Market Data and Key Metrics Changes - Approximately 20% to 25% of current Firdapse patients are cancer-associated LEMS patients, with expectations to grow this segment significantly [47][90]. - The market size for LEMS is estimated at $1,200,000,000, with the company currently holding about 25% market penetration [95]. Company Strategy and Development Direction - The company aims to expand its market leadership for Firdapse and enhance its growth through strategic initiatives targeting cancer-associated LEMS patients [8][19]. - Business development remains a core growth lever, focusing on opportunities with strategic synergy and clinical differentiation [15][54]. - The company is committed to expanding access to rare disease therapies in international markets, including Japan and Canada [13][14]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining operational excellence and delivering durable growth while addressing the needs of rare disease patients [16][34]. - The company reaffirmed its full-year total product revenue guidance of between $545,000,000 and $565,000,000 for 2025 [16][25]. Other Important Information - The company has a strong cash position of $580,700,000, allowing for financial flexibility to support R&D and strategic initiatives [6][33]. - Research and development expenses increased to $3,900,000 in Q1 2025 from $2,600,000 in Q1 2024, reflecting ongoing investments in clinical studies [32]. Q&A Session Summary Question: How much of Firdapse's growth is attributed to the Change Healthcare impact? - Management indicated that if the Change Healthcare impact is backed out, Firdapse would still be in the 15% to 20% growth range [39][40]. Question: What proportion of Fycompa patients are on the tablet versus oral suspension? - Approximately 98% of Fycompa patients are on the tablet formulation [42]. Question: How is the uptake of Firdapse among small cell lung cancer patients trending? - Currently, about 20% to 25% of LEMS patients on Firdapse are cancer-associated, with plans to increase this through screening initiatives [47][90]. Question: What are the current thoughts on business development in the changing macro environment? - The company remains focused on immediately accretive opportunities and sees the current market dynamics as beneficial for its strategy [54][55]. Question: What gives confidence in the strategy for cancer-associated LEMS? - There is significant interest from the oncology community in diagnosing and treating cancer-associated LEMS, indicating a strong unmet need [58][60].